Dual-target cell therapy for returning B-cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new cell therapy that targets two proteins (CD19 and CD20) found on certain lymphoma cells. It is for patients whose B-cell non-Hodgkin lymphoma has come back or not responded to at least two prior treatments. The goal is to see if this therapy can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of B-cell non-Hodgkin lymphoma that has come back or not improved after at least two treatments.
- You are healthy enough to be up and about (able to do light activity).
- You have at least one tumor that can be measured on a scan.
- You have not had certain prior treatments like a donated stem cell transplant or a specific type of CAR-T cell therapy.
- You are not pregnant or breastfeeding, and you do not have active hepatitis or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy that targets two proteins (CD19 and CD20) found on certain lymphoma cells. It is designed for patients whose lymphoma has not responded to or has returned after previous treatment, and who cannot or choose not to receive standard CAR-T therapy.
This trial tests a new treatment called LUCAR-20SP for people with certain types of B-cell lymphoma that have come back or not responded to prior therapy. The drug is a type of CAR-T therapy that targets the CD20 protein on lymphoma cells.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
This trial tests a new treatment made from your own immune cells (gamma-delta T cells) that are engineered to find and kill CD19-positive lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after at least two standard treatments.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
This trial tests a new CAR-T treatment that targets three proteins on lymphoma cells (CD19, CD22, and BCMA). It is for people with certain types of B-cell lymphoma that have come back or are not responding to standard treatments.
Hear when a new B-Cell Non-Hodgkin Lymphoma-Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.